Hadi Nasiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hadi Nasiri has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ali Hassanzadeh
Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Majid Ahmadi
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Morteza Akbari
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Navid Shomali
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications Alireza Goudarzian
Shahrekord University, Shahrekord, Iran
1 shared publication- Javad Ahmadian Heris
Department of Allergy and Clinical Immunology, Pediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication
Latest Publications
- Open Access
- 4 June 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 862-882
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs)
A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.
- 4 June 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 862-882
Open AccessCancer therapy by cyclin-dependent kinase inhibitors (CDKIs)
A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.
- Open Access
- 25 March 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 401-420
Detailed role of mesenchymal stem cell (MSC)-derived exosome therapy in cardiac diseases
Coronary heart disease (CHD) continues to be the leading cause of morbidity and mortality. There are numerous therapeutic reperfusion methods, including thrombolytic therapy, primary percutaneous coronary intervention, and anti-remodeling drugs like angiotensin-converting enzyme inhibitors and beta-blockers. Despite this, there is no pharmacological treatment that can effectively stop cardiomyocyte death brought on by myocardial ischemia/reperfusion (I/R) injury. For the purpose of regenerating cardiac tissue, mesenchymal stem cell (MSC) therapy has recently gained more attention. The pleiotropic effects of MSCs are instead arbitrated by the secretion of soluble paracrine factors and are unrelated to their capacity for differentiation. One of these paracrine mediators is the extracellular vesicle known as an exosome. Exosomes deliver useful cargo to recipient cells from MSCs, including peptides, proteins, cytokines, lipids, miRNA, and mRNA molecules. Exosomes take part in intercellular communication processes and help tissues and organs that have been injured or are ill heal. Exosomes alone were found to be the cause of MSCs' therapeutic effects in a variety of animal models, according to studies. Here, we have focused on the recent development in the therapeutic capabilities of exosomal MSCs in cardiac diseases.
- 25 March 2024
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 23, 401-420
Open AccessDetailed role of mesenchymal stem cell (MSC)-derived exosome therapy in cardiac diseases
Coronary heart disease (CHD) continues to be the leading cause of morbidity and mortality. There are numerous therapeutic reperfusion methods, including thrombolytic therapy, primary percutaneous coronary intervention, and anti-remodeling drugs like angiotensin-converting enzyme inhibitors and beta-blockers. Despite this, there is no pharmacological treatment that can effectively stop cardiomyocyte death brought on by myocardial ischemia/reperfusion (I/R) injury. For the purpose of regenerating cardiac tissue, mesenchymal stem cell (MSC) therapy has recently gained more attention. The pleiotropic effects of MSCs are instead arbitrated by the secretion of soluble paracrine factors and are unrelated to their capacity for differentiation. One of these paracrine mediators is the extracellular vesicle known as an exosome. Exosomes deliver useful cargo to recipient cells from MSCs, including peptides, proteins, cytokines, lipids, miRNA, and mRNA molecules. Exosomes take part in intercellular communication processes and help tissues and organs that have been injured or are ill heal. Exosomes alone were found to be the cause of MSCs' therapeutic effects in a variety of animal models, according to studies. Here, we have focused on the recent development in the therapeutic capabilities of exosomal MSCs in cardiac diseases.
- 20 March 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Aerospace and Electronic Systems
- Vol. 53 (5) , 2167-2177
PI and PWM Sliding Mode Control of POESLL Converter
The positive output elementary superlift-Luo converter (POESLLC) is a type of dc/dc converter. This dc/dc converter has an attractive advantage of a high voltage transfer gain as compared with other conventional dc/dc converters. Because of the voltage and load variations and also switching operation, the dynamic and static performances of the POESLLC are nonlinear and time varying. In order to achieve an excellent performance, a nonlinear controller is required. In this paper, a robust and fast response controller for voltage regulation of a POESLLC is presented. A proportional integral and pulse width modulation sliding mode controller are combined to control a third-order POESLLC. The proposed controller can be applied in the continuous conduction mode. Some simulations and experimental results are presented to show the effectiveness of the developed controller in different operating conditions. Furthermore, it will be shown that the developed controller is successful in suppressing the steady-state error of the output voltage of the POESLLC as well as the number of reduction of sensors.
- 20 March 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Aerospace and Electronic Systems
- Vol. 53 (5) , 2167-2177
PI and PWM Sliding Mode Control of POESLL Converter
The positive output elementary superlift-Luo converter (POESLLC) is a type of dc/dc converter. This dc/dc converter has an attractive advantage of a high voltage transfer gain as compared with other conventional dc/dc converters. Because of the voltage and load variations and also switching operation, the dynamic and static performances of the POESLLC are nonlinear and time varying. In order to achieve an excellent performance, a nonlinear controller is required. In this paper, a robust and fast response controller for voltage regulation of a POESLLC is presented. A proportional integral and pulse width modulation sliding mode controller are combined to control a third-order POESLLC. The proposed controller can be applied in the continuous conduction mode. Some simulations and experimental results are presented to show the effectiveness of the developed controller in different operating conditions. Furthermore, it will be shown that the developed controller is successful in suppressing the steady-state error of the output voltage of the POESLLC as well as the number of reduction of sensors.